Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.95 |
| ▸ | DRD3 | P35462 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | HTR1A | P08908 | 1/20 | 0.95 |
| ▸ | DRD1 | P21728 | 1/20 | 0.95 |
| ▸ | ACHE | P22303 | 1/20 | 0.95 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | HTR2B | P41595 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | HTR3B | O95264 | 1/20 | 0.71 |
| ▸ | MPO | P05164 | 1/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.71 |
| ▸ | DRD4 | P21917 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromopride SCHEMBL54497 | 0.98 | ADRA2A (1.00) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Bromopride SCHEMBL8385045 | 0.96 | ADRA2A (0.98) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Bromopride SCHEMBL18339178 | 0.95 | ADRA2A (0.95) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Bromopride SCHEMBL18338829 | 0.95 | ADRA2A (0.95) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Metoclopramide SCHEMBL678373 | 0.86 | HTR4 (0.95) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Metoclopramide SCHEMBL678957 | 0.86 | HTR4 (0.95) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Metoclopramide SCHEMBL678610 | 0.85 | HTR4 (0.93) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| Metoclopramide SCHEMBL8160010 | 0.85 | HTR4 (0.98) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| SCHEMBL11946667 | 0.84 | ADRA2A (0.76) | ADRA2ACYP2D6DRD3CYP1A2HTR1A | |
| SCHEMBL17068280 | 0.84 | ADRA2A (0.76) | ADRA2ACYP2D6DRD3CYP1A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| CN-114441663-A | Method for screening protein positive compounds by using solid phase microextraction affinity selection mass spectrum | 中国科学院上海药物研究所 | 2022-05-06 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | SYNCRIP, FUS, SARS1 | DRD2 2016/4885ADRA2A 4633/4885CYP2D6 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.